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Fabry disease is an X-chromosome-linked lysosomal storage disease characterized by 
a deficient activity or, in most males, absence of the enzyme α-galactosidase A (a-Gal A) 
leading to systemic, primary lysosomal accumulation of globotriaosylceramide (Gb3) (1). 
Recent literature refers to an overall birth prevalence of 1:40,000–170,000; however, 
such data do not allow an estimation on an actual patient number suffering from Fabry 
disease (2). Multisystem morbidity commonly develops in childhood and, with progres-
sion of the disease, life-threatening complications often occur in adulthood, including 
renal failure, cardiovascular dysfunction, neuropathy, and stroke (3–6). Life expectancy 
is reduced by an average of 15 years in female patients and 20 years in male patients 
(7, 8). The pathognomonic Gb3 accumulation has been repeatedly observed over the 
past decades by many groups in vascular endothelial and smooth muscle cells, cardio-
myocytes, cardiac conduction tissue, and valvular fibroblasts (3). Although incompletely 
described, it is likely that inflammatory and neurohormonal mechanisms are involved in 
subsequent cellular and vascular dysfunction, leading to tissue ischemia, hypertrophy, 
and fibrosis (9). Furthermore, recently published works on cardiomyocyte dysfunction 
and conduction tissue involvement have suggested that cardiac dysfunction may reflect 
increased myocardial nitric oxide production with oxidative damage of cardiomyocyte 
myofilaments and DNA, causing cell dysfunction and death, and accelerated conduction 
with prolonged refractoriness and electric instability (10, 11).
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CARDiAC MAniFeSTATiOnS
Cardiac involvement of the disease has been recognized as a common end-organ complication 
since the earliest reports and is an undisputed driver of morbidity and mortality in Fabry disease. 
Intracellular accumulation of Gb3 leads through complex cellular cascades and mechanisms that 
are still not fully explained to irreversible cardiac damage (Figure 1). As a consequence, signifi-
cant morbidity as well as early death due to heart failure and, most importantly, life-threatening 
ventricular arrhythmias may result (12). Left ventricular hypertrophy is a key feature and occurs 
in up to 50% of males and one-third of females (4). In most cases, left ventricular hypertrophy 
is concentric; however, an asymmetrical variety with septal thickening and posterior wall fibrotic 
thinning may be present in an advanced stage of the disease. Mild left ventricular diastolic dys-
function is seen early in the disease process and progresses to severe forms in later stages. Right 
ventricular hypertrophy is also common and may progress to right ventricular dilatation (13). The 
fibrotic process in Fabry cardiomyopathy starts with intramural, and later transmural, involvement 























FiGURe 1 | Simplified course disease pathogenesis in Fabry disease. 
LVH, left ventricular hypertrophy.
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accumulation of Gb3 begins very early in life, left ventricular 
hypertrophy most commonly manifests itself only decades later, 
at an average age of 32 years in men and 40 years in women (12). 
This suggests that the detection of left ventricular hypertrophy 
might not be suitable for the recognition of early stages of the 
disease. Furthermore, it has become evident that the severity 
of baseline left ventricular hypertrophy and fibrosis determines 
the cardiac outcome with enzyme replacement therapy and that 
the best treatment outcomes can be obtained when treatment is 
started early.
COnDUCTiOn ABnORMALiTieS 
AnD ARRHYTHMiA BURDen in 
FABRY DiSeASe
Commonly reported arrhythmia and electrocardiographic find-
ings include bradycardia and PQ-interval shortening, which 
has been shown to be due to shortening of the P-wave duration 
and one of the first signs of cardiac involvement (15) (Figure 2). 
Further abnormalities include PQ-interval prolongation, repo-
larization abnormalities, and atrioventricular block. Of note, 
increasing age has been demonstrated to be associated with 
PQ- and QRS-interval prolongation and left QRS axis deviation 
as well as a progressive sinus and atrioventricular node disease, 
necessitating a close monitoring for bradyarrhythmias and the 
implantation of a pacemaker (16). Accordingly, prolongation of 
the PQ interval, whether shortened or within normal limits at 
baseline, is a very common finding in the natural history of FD 
patients, more likely reflecting a progressively increasing disease 
burden and age-related degenerative processes. The fact that any 
change in PQ interval may be found at any stage of the disease 
may only be addressed with speculative explanatory approaches 
and include the hypothesis that the process of intracardiac Gb3 
deposition and treatment response rather follows stochastic rules 
and may, for instance, start in the atrioventricular perinodal 
tissue before reaching a homogenous and thus stationary 
phase of accumulation in later stages of the disease, when trig-
gered cascades of hypertrophy, proliferation, and fibrosis on a 
cellular–molecular level overrule the importance of Gb3 storage 
and its direct effects per se.
A recent retrospective chart review of 19 patients on ERT also 
revealed a high utilization of antibradycardic device therapy and 
suggested that sudden cardiac death in Fabry cardiomyopathy 
may rather be related to bradycardia than to (in this report) an 
uncommonly observed significant ventricular arrhythmia (17), 
which, after all, remains the most life-threatening condition (18, 
19). Longitudinal studies suggest that arrhythmias (including 
atrial fibrillation and ventricular tachycardia) occur in 27–42% of 
male and 27% of female patients with Fabry disease (14). Of note, 
all these factors can be encountered in patients with preserved 
left ventricular function and in the absence of left ventricular 
hypertrophy or valve disease (20, 21). While different authors 
have suggested that the prevalence of paroxysmal atrial fibril-
lation is up to four times greater in Fabry patients than in the 
general population, such numbers have to be treated with caution 
(12, 19). Most of the included patients displayed an increased 
left atrial diameter, diastolic dysfunction, and increased left 
ventricular wall thickness, all being predicting factors for atrial 
fibrillation. Prevalence numbers for arrhythmic episodes obvi-
ously increase from the onset of overt Fabry-associated cardi-
opathy in an exponential course with left ventricular remodeling 
and hypertrophy, elevated left ventricular and atrial pressures, 
interstitial fibrosis, and, finally, dilatative cardiomyopathy in end 
stages of the disease (22).
vALUe OF THe eLeCTROCARDiOGRAM 
in DiAGnOSiS
Nevertheless, over all these years, the use of the electrocardiogram 
remained somehow neglected and retained for the measurement 
of a shortened or prolonged PQ interval. Changes of the PQ 
interval have been reported in case studies and observational data 
from registries and may be the result of different phenomena (23, 
24). However, whether abnormalities in the PQ-interval duration 
were of diagnostic value in patients with Fabry disease or if they 
correlated with specific clinical or echocardiographic findings 
remained unclear. As a matter of fact, a first study “demystified” 
electrocardiography in Fabry disease and reported the relatively 
low prevalence (14%) of atrioventricular conduction abnormali-
ties in a large cohort (N = 207) of patients newly diagnosed with 
Fabry disease, demonstrating that the short PQ interval cannot 
be considered a robust and sensitive sign for the diagnosis of this 
disease (25). Of note, no significant differences in atrioventricular 
conduction comparing patients with and without left ventricular 
hypertrophy were found, suggesting that neither PQ-interval 
shortening nor atrioventricular block showed any correlation 
with the severity of the cardiac involvement. These initial findings 
indicated that the duration of the PQ interval has a low diagnostic 
yield for early recognition and assessment of disease in patients 
with a Fabry-related cardiopathy, leading further to a first sys-
tematic analysis of early electrocardiographic changes in patients 
without signs of left ventricular hypertrophy and diastolic dysfunc-
tion (15). Here, accelerated depolarization intervals (shortening 
of P-wave duration and QRS width), increased repolarization 
Atrium
 Bradyarrhythmia, impaired
HRV, SVES, Aflu, AF 
Ventricular repolarizaon
 Negave ST-T, strain paern
AV-conducon
 PQ „shortening“ by P wave shortening, 
AV-Block
Ventricular depolarizaon
 LBBB/RBBB, pseudoinfarct Q, high voltage, 
VES, NSVT, sust VT, VF 
FiGURe 2 | Schematic illustration of the most prevalent conduction abnormalities and arrhythmia. HRV, heart rate variability; SVES, supraventricular 
extrasystole; Aflu, atrial flutter; AF, atrial fibrillation; LBBB, left bundle branch block; RBBB, right bundle branch block; VES, ventricular extrasystole; NSVT, 
non-sustained ventricular tachycardia; sust VT, sustained ventricular tachycardia; VF, ventricular fibrillation.
3
Namdar Electrocardiographic Changes and Arrhythmia in Fabry Disease
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2016 | Volume 3 | Article 7
duration (QT and QTc), and more pronounced repolarization 
dispersion (QTc dispersion and Tpeak–Tend dispersion) could 
be shown in Fabry patients. These early stage patients had indeed 
shorter PQ intervals as compared to age and heart rate-matched 
healthy controls, but PQ intervals were mostly still within the 
“normal” range (i.e., 120–200 ms) and with similar mean values 
as in the former analysis (139 ± 29 vs. 131 ± 18 ms) (25). Most 
importantly, shortening of the P-wave duration was found to 
be the main contributor to the shorter PQ interval and, while 
both P-wave and PQ-interval duration differ significantly from 
healthy subjects, P-wave duration yielded a higher diagnostic 
performance (92% sensitivity and 80% specificity) (15).
Among different conceivable mechanisms (such as changes in 
P-wave morphology with changes in heart rate; more synchronous 
activation of the atria through the sinus node activity preferentially 
exiting closer to Bachmann’s bundle; and accumulation of Gb3 in 
and around the crista terminalis) having in theory an accelerated 
intra-atrial conduction as the common denominator, we think 
that changes on a cellular or subcellular level might finally yield 
the explanation for the observed electrocardiographic signs. As a 
matter of fact, an enhanced conduction velocity has been associ-
ated with an increase in the diameter of conducting cells and 
thus alterations of transmembranous ion currents by many drugs 
and toxins (26). This suggests that the same may be the case for 
Gb3, which is known to directly interact with cellular membrane 
compounds, such as ion channels involved in action potential 
propagation (9, 27). The reported shorter QRS width further 
suggested that an enhanced conduction velocity might equally 
occur within the ventricles. Clinical cardiac electrophysiologic 
case studies have specifically excluded septal accessory pathways 
as an underlying cause for the observed electrocardiographic 
changes in Fabry disease (28, 29). Furthermore, a recent study 
showed a normalization of the QTc interval, PQ interval and, 
most interestingly, P-wave duration under enzyme replacement 
therapy along with a reduced disease burden, suggesting that the 
observed electrocardiographic changes might, at least to some 
degree, have a link to the Gb3 storage (30). While it has been 
shown for glycogen storage diseases that similar phenomena are 
directly caused by glycogen storage acting as independent con-
ducting elements within the myocardial tissue in and around the 
atrioventricular node, none of the investigations could confirm 
the same for patients with Fabry disease so far (31). It is further 
noteworthy that an accumulation in and around the atrioven-
tricular node does not explain changes in P-wave duration giving 
rise to the question whether previous reports on PQ-interval 
shortening alone in other storage diseases should be revisited 
with respect to this observation. These generated the hypothesis 
that electrocardiographic parameters may be of considerable help 
for an earlier recognition of patients, eventually earlier initiation 
of enzyme replacement therapy before otherwise irreversible 
organ manifestations occur and, last but not least, be useful as 
follow-up parameters during the treatment.
However, as various electrocardiographic parameters change 
with macroscopic myocardial changes (QRS width and repolari-
zation indices with left ventricular hypertrophy, P-wave altera-
tions with left atrial enlargement), an assessment of their value in 
the differential diagnosis of hypertrophic cardiopathies has been 
performed (32). As expected, mean left atrial size in Fabry patients 
with left ventricular hypertrophy was almost double when com-
pared with early stage patients. Accordingly, these enlarged left 
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atrial dimensions might have outbalanced presumable shorter PQ 
interval and P-wave durations in Fabry patients and thus impaired 
their diagnostic value. To overcome this shortcoming, the authors 
chose PQ interval minus P-wave duration in lead II (Pend – Q) 
as a more robust measurement for atrioventricular conduction. 
It turned out to have an even higher diagnostic performance for 
the recognition of Fabry disease as compared to the commonly 
used PQ interval. Furthermore, a two-step approach combining 
QTc duration with the above-discussed measure showed a high 
diagnostic performance for the differentiation of Fabry disease 
from amyloidosis, and a novel index based on these parameters 
proved very useful for the differentiation of the two entities Fabry 
and amyloidosis from hypertensive heart disease, familiar hyper-
trophic cardiomyopathy, and left ventricular hypertrophy owing 
to significant aortic stenosis.
vALUe OF THe eLeCTROCARDiOGRAM 
in DiSeASe STAGinG
Naturally, the thorough investigation of baseline electrocardio-
graphic parameters and their diagnostic value in the recognition 
of early-stage and differentiation of late-stage Fabry patients begs 
the question whether these and possibly other parameters might 
have any value in disease staging.
Electrocardiographic changes in a large group of patients 
with Fabry disease in different disease stages have recently been 
investigated. Here, the main findings were ST- and T-alterations 
(ST-declines or elevation; T-wave inversion) giving a clue toward 
myocardial fibrosis. As a matter of fact, these alterations, mainly 
found in the lateral leads V5 and V6, fit very well with the region 
where late enhancement (a sign for focal fibrosis) in magnetic res-
onance tomography can be seen first. ST- and T-alterations have 
already been reported in patients with Fabry disease. However, 
they have been rather misinterpreted as infarct associated lesions 
in the past since macrovascular coronary artery disease is very 
rarely encountered in these patients (24, 33). While the detection 
of fibrotic areas by one single electrocardiographic parameter 
did not emerge feasible, it is nevertheless reasonable to state that 
replacement fibrosis is very unlikely when no ST- or T-alterations 
are observed (34).
The importance of this finding is manifold. First of all, in 
“electrocardiography negative” Fabry patients, the cost and time 
consuming process of a cardiac magnetic resonance tomography 
might not be necessary. Second, as the presence of fibrosis evidently 
plays a crucial role in terms of a higher incidence of ventricular 
arrhythmias and poor prognosis in patients with ischemic and 
non-ischemic cardiopathies, these findings might have a major 
impact on further diagnostic and therapeutical strategies (35, 36). 
Different mechanisms are considered to be involved in the patho-
genesis of ventricular arrhythmias particularly in the presence of 
fibrosis. While in ischemic cardiopathies, the main mechanism is 
assumed to be scar-based reentry, the arrhythmogenic substrate 
in non-ischemic cardiopathies has been demonstrated to be repre-
sented by an increased myocardial collagen content and regional 
fibrosis (37). Moreover, electrophysiological studies have revealed 
that patients with sustained ventricular tachycardia show a greater 
degree of myocardial fibrosis than patients without arrhythmias 
and that the basal electrocardiographic and intracardiac electro-
gram abnormalities corresponded very well to the site of origin 
of the these tachycardias (38). Accordingly, a number of such 
electrocardiographic abnormalities, invariably coming along with 
micro- and macroscopic myocardial changes, have been linked 
to potentially life-threatening reentrant ventricular arrhythmias 
(39, 40) and shown to be prevalent not only in patients with overt 
left ventricular hypertrophy but also in an early stage of the dis-
ease (15, 32). These and recently published data indicate that the 
observed electrocardiographic surrogates in conjunction with a 
fibrotic substrate may be associated with the increased propensity 
of Fabry patients to develop ventricular arrhythmias (41).
Unfortunately, the prevalence of life-threatening arrhythmia 
in patients with Fabry disease is not well documented so far. This 
might be due the paucity of studies involving large populations. 
Non-sustained ventricular tachycardia has been reported to occur 
in 38% of men with Fabry disease aged more than 50 years in a 
study with 78 consecutive patients. While none of these patients 
had evidence of coronary heart disease as an underlying cause, 
some already had advanced left ventricular hypertrophy (and 
possibly fibrotic areas) and might therefore have been susceptible 
to ventricular arrhythmias (19). Results from the International 
Fabry Outcome Survey with 714 patients depicted the prevalence 
of palpitations or documented arrhythmias (not further specified) 
as 15 and 21%, respectively, in untreated men and women. The 
average age of these two groups was 26 and 45 years, respectively. 
Although these numbers suggest that arrhythmias might occur 
earlier than the development of left ventricular hypertrophy, it is 
important to note that the prevalence of left ventricular hypertro-
phy even in these two groups was 33 and 21%, respectively (12). 
However, an earlier analysis demonstrated that QTc prolongation 
and pronounced repolarization abnormalities are present before 
echocardiographic signs of left ventricular hypertrophy are 
detectable (15). These data indicate that conduction abnormali-
ties do not exclusively occur as a result of the latter but may result 
from a Fabry-specific disease process and that the temporal as 
well as the causal interrelationship between the development of 
conduction abnormalities and/or arrhythmias and left ventricular 
hypertrophy with or without fibrosis remain unclear.
OUTLOOK AnD FUTURe PeRSPeCTiveS
Despite all efforts over the past decades for a better understand-
ing of disease mechanisms in Fabry disease, many questions and 
unmet needs remain with regards to a satisfying management of 
affected patients.
To begin with, the presentation and clinical course of this 
disease is very heterogeneous. Although its progressive character 
with life-threatening multiorgan manifestations develops gener-
ally during the third and fourth decade of life, many symptoms 
of the disease can occur before 10 years of age, frequently result-
ing in a mean time between the onset of symptoms and correct 
diagnosis in these patients of over 15  years, emphasizing the 
importance of an increased awareness. As enzyme replacement 
therapy is available, earliest possible recognition and treatment 
of these patients and family members is of utmost importance. 
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Although  substantial progresses have been made in the past 
years studying histopathological changes associated with Gb3 
accumulation in animal model studies using GLA-knock-out 
mice, they remain, for the time being, of limited value for Fabry 
disease-associated cardiomyopathy, since they lack of lysosomal 
Gb3 storage in vascular endothelial cells and cardiomyocytes (42).
Several electrocardiographic characteristics have been 
described to occur not only early in the disease course but also 
before morphologic alterations develop, as most of the included 
patients had normal echocardiograms. Whether these electrocar-
diographic abnormalities have a more diagnostic value in patients 
with Fabry disease and whether they correlate with specific 
clinical or echocardiographic findings remains elusive and are a 
matter of current investigations. In this regard, electrophysiologic 
studies in patients with a confirmed diagnosis in any stage of the 
disease are needed.
Furthermore, a prospective cohort study to clarify the prog-
nostic significance of conduction abnormalities and arrhythmias, 
their development under enzyme replacement therapy, and the 
causes of mortality does not exist to date. Therefore, in contrast 
to the prognostic significance of left ventricular hypertrophy, 
the question remains open as to what extent arrhythmias are 
of clinical or even prognostic significance that should be taken 
seriously in Fabry disease. Finally, despite many questions left, 
these parameters may identify patients at a high risk to justify 
the use of an implantable cardioverter defibrillator in order to 
treat malignant ventricular arrhythmias, one of the most dreaded 
complications of Fabry disease.
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